MicroRNAs (miRNAs) are a recently discovered class of post-transcriptional regulators that induce target messenger RNA degradation or translation inhibition. miRNA-155 (miR-155) is an important regulator of immune cells both in humans and mice, by which these cells play critical roles in the pathogenesis of rheumatoid arthritis (RA). Recent findings showed that expression of miR-155 was elevated in RA patients and arthritis models. Moreover, miR-155 overexpression or knockdown performed significantly in the development of arthritis. This review summarizes the recent findings with respect to miR-155 in immune responses and the underlying mechanisms responsible for miR-155-related autoimmune arthritis. Hopefully the information obtained will benefit the development of novel therapeutic strategies.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease affecting 1% of the world population and is one of the most prevalent causes of disability worldwide. 1 It is characterized by chronic, destructive arthritis resulting from complex alterations of not only the adaptive immune system, but also the innate immune system. To date, the pathogenesis of RA has not been clearly elucidated, but it is thought that the interaction of genetic, immunological and environmental factors contributes to the disease. 2 Even though animal models of arthritis and treatment in patients with RA have provided evidence that T cells, B cells, and the orchestrated interactions of pro-inflammatory cytokines are involved in the pathophysiology of RA, a substantial number of RA patients still do not respond sufficiently to current treatment options. Therefore, searching for new therapeutic targets is needed. 3 MicroRNAs (miRNAs) are a large family of highly conserved noncoding RNA molecules that are linked to a wide range of biological processes such as cellular proliferation, differentiation and apoptosis. miRNAs can bind the 3'-untranslated region of target messenger RNA (mRNA) to either block the target mRNA translation or to induce target mRNA degradation. 4, 5 miRNAs are first transcribed by RNA polymerase II into a long primary miRNA (pri-miRNA) transcript. 6, 7 Then, the pri-miRNA is cleaved by Drosha and its partner protein DGCR8 (DiGeorge critic region 8) into an approximately 70-nucleotide precursor miRNA (pre-miRNA) molecule. [8] [9] [10] [11] The pre-miRNA is exported from the nucleus into the cytoplasm via Exportin 5. In cytoplasm, it is cleaved by Dicer along with its partner protein into approximately 19-24 nucleotides miRNA duplexes. 12 One strand of the miRNA duplex is then loaded into the RNA-induced silencing complex (RISC). This complex directs the miRNA to the target mRNAs.
miR-155 has been recognized as an important regulator for immune cell development, as well as immune response. miR-155 is encoded within a region known as B cell integration cluster (Bic) gene, identified originally as a frequent integration site for the avian leukosis virus. 13, 14 miR-155 deficient (miR-155 À/À ) mice showed defective B cell immunity, such as down-regulated numbers of germinal center B cells. 15, 16 miR-155 À/À B cells led to reduced extrafollicular and germinal center responses, and immunoglobulin G1 (IgG1) antibodies production. 17 Interestingly, overexpression of miR-155 in activated cluster of differentiation 4 (CD4) + T cells promoted T-helper 1 cell (Th1) differentiation, 18 and miR-155 À/À T cells under Th17 polarization condition revealed reduced production of the Th17 cytokines interleukin (IL)-17 and IL-22. 19 Available evidence suggested that expression of miR-155 was abnormal in RA patients and arthritis models. In addition, functional analysis revealed that overexpression of miR-155 or miR-155 knockdown resulted in aberrant production of auto-antibodies and pro-inflammatory cytokines, which correlate with the pathogenesis of arthritis. The strong association of this factor with autoimmune arthritis on multiple levels compels us to systematically review what has been published recently on the crucial nature of miR-155 in relation to RA gaining attention for its regulatory capability in autoimmune arthritis. The information obtained may lead to a better understanding of the pathogenesis and development of novel therapeutic strategies for this systemic autoimmune disease. 12 
ROLE OF MIR-155 IN IMMUNE CELLS
Among the many miRNAs, current studies primarily focus on the roles of miR-155 in immune cells in terms of its physiological functions and potential signalling mechanisms (Fig. 1) . With respect to B cells, both the number of germinal centers and antibody production were greatly reduced in miR-155 À/À mice. 15 In a transgenic mouse model expressing miR-155 under the control of El enhancer and V H promoter (El-miR-155), dysregulated B cell development led to the marked accumulation of preB cells in these mice, and they developed acute lymphoma owing to the abnormal proliferation of B cells. 20 Expression of miR-155 negatively correlated with SH-2 containing inositol 5' polyphosphatase 1 (SHIP1) in human CD14 + monocytes and CD68 + macrophages, by which forced expression of miR-155 inhibited SHIP1 expression in peripheral blood-derived CD14 + cells. 21 miR-155 spontaneously induced the enhanced generation of tumor necrosis factorm (TNF)-a and IL-6 in peripheral bloodderived macrophages in humans. 21 Similarly, overexpressed miR-155 in human monocyte-like THP1 cells generated more TNF-a and IL-1b in response to sodium monourate. 22 Up-regulation of miR-155 in macrophages promoted inflammation and M1 polarization, but inhibited M2 polarization. 23 In miR-155 À/À mice, bone marrow-derived dendritic cells (BMDC) generated fewer pro-inflammatory cytokines, such IL-6 and IL-12 in response to lipopolysaccharide (LPS). [24] [25] [26] miR-155 overexpression also promoted DC apoptosis, 27 while inhibition of miR-155 induced DC maturation defects, suppressed DC apoptosis, failure to activate T cells but negatively regulated pro-inflammatory cytokine production. 15, 27, 28 After treatment with the Toll-like receptor (TLR)7 agonist R837, miR-155-transfected plasmacytoid DCs produced less interferon (IFN)-a/b and TNFa. 29 T cells from miR-155 À/À mice showed an increased tendency to differentiate into Th2 type cells, and they enhanced Th2 type cytokine production. 15 On the other hand, increased levels of miR-155 in activated CD4 + T cells are able to induce Th1 cell differentiation by targeting the IFN-c receptor alpha chain.
18 miR-155
mice also generated lower numbers of Th17 cells. 24 Furthermore, miR-155 deficiency led to reduced regulatory T cell (Treg) numbers, and down-regulated STAT5 (signal transducers and activators of response 5) phosphorylation and IL-2 receptor signaling owing to insufficient SOCS1 (suppressor of cytokine signaling 1) suppression. 30 Overexpressed miR-155 expanded natural killer (NK) cell numbers and arrested at their terminal differentiation, but increased cytotoxic activity against tumor cells and pathogens. 31 miR-155 knockdown accelerated NK cell maturation but reduced their population and impaired NK cell expansion in response to infection. 31 Together, these data indicated that miR-155 plays different roles in distinct immune cells.
ABERRENT EXPRESSION OF MIR-155 IN AUTOIMMUNE ARTHRITIS
In RA patients, miR-155 expression was significantly increased in peripheral blood mononuclear cells compared with healthy controls. [32] [33] [34] Expression of TNF-a and IL-1b were significantly higher in the patients with RA than in the patients with osteoarthritis (OA) or healthy controls. 32 Increased expression of miR-155 in RA patients was positively related to TNF-a, IL-1b levels, C-reactive protein, erythrocyte sedimentation rate (ESR) levels and Disease Activity Score of 28 joints (DAS28), respectively. 32, 33 The copy-numbers of miR-155 transcripts in purified peripheral blood CD14 + monocytes
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International Journal of Rheumatic Diseases 2017; 20: 1631-1637 of RA patients were significantly higher than the CD14 + monocytes of healthy controls, and the miR-155 copynumbers correlated with DAS28 scores, ESR levels, total joint and swollen joint counts. 35 There was an increased expression of miR-155 copy-number in monocytes from patients positive for anti-citrullinated peptide antibodies (ACPA) compared with ACPA negative patients. 35 Similarly, miR-155 is expressed at higher levels in RA CD19
+ cells compared with CD19 + cells isolated from healthy controls, and CD19 + cells isolated from peripheral blood of ACPA positive patients showed higher miR-155 expression than healthy controls and ACPA negative RA patients, respectively. 36 
Interestingly, CD19
+ cells from synovial fluid (SF) showed significantly higher miR-155 expression than CD19 + cells isolated from paired peripheral blood of RA patients. 36 Kurowska-Stolarska et al. reported that miR-155 is significantly expressed in RA but not OA synovial biopsies, mainly in the lining layer and to a lesser extent in the sublining layer, and double immunofluorescence staining revealed that miR-155 is expressed in a majority of CD68 + macrophages in the RA membrane-lining layer.
21,37 miR-155 is strongly elevated in RA SF-derived CD14
+ cells compared to those obtained from peripheral blood CD14 + cells. 21 These data suggested that elevated miR-155 expression is present in RA peripheral blood or synovium.
MIR-155 REGULATES THE GENERATION OF AUTOIMMUNE-RELATED COMPONENTS IN RA
Evidence has shown that miR-155 contributes to the pathogenesis of RA due to its increasing the production of autoimmune-related components such as proinflammatory cytokines and chemokines. CD19 + B cells from RA patients transfected with anti-miR-155 showed a significant increase of PU.1 expression compared with RA B cells teated with control inhibitor. 36 Interestingly, B cells from ACPA positive RA patients transfected with miR-155 and stimulated with anti-IgM, CD40L, IL-21 or B-cell activating factor showed strongly increased total IgG production. In contrast, miR-155 inhibition results in a substantial decrease in antibody production, indicating that miR-155 in RA B cells is a key post-transcriptional regulator of antibody production. 36 Overexpression of miR-155 in RA patients' peripheral blood CD14 + monocytes triggered the generation of cytokines and chemokines strongly implicated in RA synovitis, such as TNF-a, IL-6, IL-1b, IL-8, chemokine ligand (CCL)3, CCL3, CCL4, CCL5, CCL8, but decreased IL-10, C-C chemokine receptor type 2 (CCR2) production. 21, 35, 38 When miR-155 overexpressed CD14 + cells were induced into macrophages, there was higher expression of TNF-a and IL-6. In addition, miR-155 overexpressed CD14 + cells incubated with RA SF-triggered TNF-a production, but this effect was abrogated in cells transfected with miR-155 antagomir. 21 RA synovial CD14 + cells transfected with miR-155 antagomir suppressed the generation of TNF-a. miR-155 overexpression in peripheral blood CD14 + cells significantly down-regulated SHIP-1 expression, whereas inhibition of miR-155 strongly up-regulated the expression of SHIP-1 in RA SF CD14 + cells. 21 In RA patients' macrophages, miR-155 overexpression produced significantly more TNF-a, IL-1b but less SOCS1, while miR-155 knockdown reduced the expression of TNF-a and IL-1b but increased SOCS1. 32 Moreover, Jing et al. generated a miR-155 genome knockout RAW264.7 macrophage using the clustered regulatory interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (CAS9) technology. They showed that endogenous miR-155 gene mutation up-regulated SHIP1, reduced production of TNF-a, IL-6 and IL-12. 39 Collectively, these data indicated that miR-155 can directly target human PU.1, SHIP-1, SOCS1 for degradation, and the chronic pro-inflammatory phenotype of immune cells in RA patients may be controled by aberrant expression of miR-155.
MIR-155 IN THE DEVELOPMENT OF RA
Aberrant miR-155 expression in the autoimmune disorder predicts the participation of this inflammatory factor in the initiation and progression of the disease. and IFN-c than did CD4 + T cells from WT mice, and WT mice immunized with collagen generated strongly high titers of collagen-specific IgG2a and IgG1 than did miR-155 À/À mice. 19, 21 When the arthritogenic serum was intraperitoneally injected into WT and miR-155 À/À mice, both groups of animals developed arthritis, but the grip strength scores were significantly higher in miR-155 À/À mice compared to WT mice, accompanied by a significant reduction in the extent of bone erosions, and reduced numbers of osteoclasts in the hind paws in miR-155 À/À mice. 19 Bone marrow macrophages of miR-155 À/À mice stimulated with macrophage colony-stimulating factor and receptor activator of nuclear factor kappa-B ligand (RANKL) showed a reduced generation of mature osteoclasts compared to that in WT mice, suggesting a defect in RANKL-dependent osteoclastogenesis in myeloid cells in miR-155
mice. Together, these findings demonstrated that the presence of miR-155 is required for the development of arthritis (Fig. 2) . In RA synovial fibroblasts (RASFs), enforced expression of miR-155 led to a substantial reduction in the constitutive expression of matrix metalloproteinase 1 (MMP-1), MMP-3 as compared with that in cells transfected with scrambled control. 37 RA fibroblast-like synoviocytes (FLS) transfected with miR-155 mimic decreased MMP-3, inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) levels, but silencing of miR-155 in RA-FLS significantly enhanced MMP-3 and IKBKE levels. 33 miR-155 silencing enhanced RA-FLS proliferation by about 1.91-fold, and inhibition of cell proliferation to about 84.40% when miR-155 was upregulated. RA-FLS also showed a diminished invasion when transfected with miR-155 mimic, but miR-155 silencing enhanced invasion. These data indicated that miR-155 may negatively affect RASFs and RA-FLS in arthritis in terms of an inflammatory environment, and miR-155 may target IKBKE, and repress MMP-3 and MMP-1. Previous studies showed that IKBKE transcripts were identified as actual targets of miR-155. 40 IKBKE was demonstrated to play a key role in MMP gene expression and subsequent joint destruction in arthritis. 41 In addition, MMPs, especially MMP-3, have been shown to associate with proliferation and invasion of RA-FLS. 42 Therefore, it is possible that miR-155 may suppress the production of MMPs through down-regulating IKBKE, and decreased MMPs induced by miR-155 may contribute to the suppression of proliferation and invasion in RA. RA is a chronic inflammatory disorder leading to irreversible joint damage. Synovial fibroblasts derived from arthritis are involved in the processes of joint destruction. RASFs showed elevated expression of pro-inflammatory genes and matrix-destructive enzymes. Thereby, methods to up-regulate miR-155 expression locally in arthritic joints might reduce the expression of certain MMPs, and control excessive tissue damage due to inflammation, preventing the destructive properties of RASFs.
CONCLUSION
Numerous studies in the field have accumulated a significant amount of knowledge and understanding regarding the biological functions of miR-155. Aberrant miR-155 expression alters innate/adaptive immune responses and contributes to the development of diseases. The understanding of the immunopathological mechanism of RA has been gradually evolving with budding studies on evaluating the important role of miR-155. Although much remains to be clarified in regard to the roles of miR-155 in RA, current data are highly suggestive of the therapeutic potential of miR-155 in RA.
Further study of miR-155 function and its respective targets is also crucial and will provide a better understanding as to the molecular mechanisms underpinning autoimmune arthritis pathogenesis. Future research will investigate and identify the targeting genes of miR-155 in different immune cells so as to facilitate the understanding of the molecular mechanisms of disease development and progression. 43 This may help to relate miR-155 expression to the altered expression of different protein-coding genes in different immune responses. In addition, more studies should give new information regarding miR-155 expression and the altered expression of proteins, which can result in novel treatment strategies for this disease.
